Recent Updates
Recently added Catalysts
ARTV Positive Sentiment

Cell & Gene The Podcast: The Future of NK Cell Therapy for Autoimmune Disease

Thursday, January 16, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Christopher Horan from Artiva Biotherapeutics discusses the benefits of natural killer (NK) cells in autoimmune disease therapy on Cell & Gene: The Podcast. He highlights their safety and efficacy compared to T cells and explains Artiva's innovative manufacturing approach for scalable NK cell production. The conversation emphasizes the potential of NK cells for off-the-shelf therapies.
Price reaction · baseline $7.12 (2025-01-15 close) · hit pre-market · clean, no other ARTV news in the window
day 0 close · peak
-4.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • NK cells offer safety and efficacy advantages over T cells.
  • Artiva's manufacturing approach enables scalable production.
  • NK cells are promising for off-the-shelf cell therapy products.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+215%
120-day peak, hindsight
Typical move
13.1%
average across 2 past catalysts
Cash runway
~51 mo
Minimal dilution risk
Lead asset
Allogeneic NK Cells
Phase 2 · Refractory Rheumatoid Arthritis (RA)

Full Press Release Details

Christopher Horan, Chief Technical Operations Officer, Artiva Biotherapeutics joins Cell & Gene: The Podcast Host, Erin Harris, to discuss the advantages natural killer (NK) cells have offer over T cells in terms of safety and efficacy for autoimmune disease. They take a deep dive into the key factors that make NK cells promising for ‘off-the-shelf’ cell therapy products. They cover Artiva’s “manufacturing first” approach to enabling scalable NK cell production, and much more.

Frequently Asked Questions

What are the advantages of NK cells over T cells?

NK cells offer enhanced safety and efficacy for treating autoimmune diseases compared to T cells.

What is Artiva's approach to NK cell production?

Artiva employs a 'manufacturing first' strategy to enable scalable production of NK cells.

Why are NK cells considered promising for therapy?

NK cells are seen as promising for 'off-the-shelf' cell therapy products due to their advantages.

ShareAdd on Google
Tags: ARTV Viatris Investor Conferences Healthcare Artiva Biotherapeutics NK cells autoimmune disease cell therapy T cells
Last updated: Jan 16, 2025

Biotech snapshot

Cash runway
$349M liquidity · $7M/mo burn
~51 mo
Minimal dilution risk
Lead asset
Allogeneic NK CellsPhase 2
Refractory Rheumatoid Arthritis (RA) →

Catalyst track record

+215%
best trade around ARTV's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for ARTV.

See every catalyst's timing & PoA →